Beam has a couple of therapies targeting rarer diseases than SCD, like alpha-1 antitrypsin deficiency (AATD) and glycogen storage disease type 1a (GSD1A). In my view, these markets have lower ...

May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq ... to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic ...

FinWise Bancorp (NASDAQ:FINW) said it has been added as a member of the U.S. small-cap Russell 2000 index. The addition will be effective after the U.S. market opens on June 30 as part of the 2025 ...

has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing ...